Flamingo-01 Phase III GP2 Product Press Releases Email Alerts

ABOUT
- MANAGEMENT TEAM
- BOARD OF DIRECTORS
TECHNOLOGY
- OUR GLSI-100 CANCER IMMUNOTHERAPY PRODUCT
- CANCER AND IMMUNOTHERAPY OVERVIEW
CLINICAL TRIALS
- COMPLETED CLINICAL TRIALS
- FLAMINGO-01 PHASE III CLINICAL TRIAL
INVESTORS & MEDIA
CONTACT

ABOUT
- MANAGEMENT TEAM
- BOARD OF DIRECTORS
TECHNOLOGY
- OUR GLSI-100 CANCER IMMUNOTHERAPY PRODUCT
- CANCER AND IMMUNOTHERAPY OVERVIEW
CLINICAL TRIALS
- COMPLETED CLINICAL TRIALS
- FLAMINGO-01 PHASE III CLINICAL TRIAL
INVESTORS & MEDIA
CONTACT

Press Releases

Investors

Overview
News & Events
Company Info
- Presentations
- FAQ
Stock Info
SEC Filings
Governance

News & Events
Press Releases
IR Calendar
Email Alerts

Year

Nov 21, 2023 6:00am EST

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

We're sorry, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please enable JavaScript in your browser and reload the page.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

All Press Releases

All SEC Filings

10-K & 10-Q Reports

Current Reports

Insider Transactions

Proxy Information

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tear Sheet
RSS Feed

Copyright © 2026

Greenwich LifeSciences, Inc.

CLINICAL TRIALS

INVESTORS & MEDIA

Copyright © 2026

Greenwich LifeSciences, Inc.

CLINICAL TRIALS

INVESTORS & MEDIA